Regeneron Pharmaceuticals, Inc. (REGN) Earns Outperform Rating from Sanford C. Bernstein


's stock had its "outperform" rating reissued by research analysts at Sanford C. Bernstein in a research note issued on Thursday. They presently have a $410.00 price objective on the biopharmaceutical company's stock, down from their previous price objective of $420.00.



from Biotech News